Modeling Dominant and Recessive Forms of Retinitis Pigmentosa by Editing Three Rhodopsin-Encoding Genes in Xenopus Laevis Using Crispr/Cas9

Joanna M. Feehan1,2, Colette N. Chiu1, Paloma Stanar2, Beatrice M. Tam1, Sheikh N. Ahmed2 & Orson L. Moritz1

The utility of Xenopus laevis, a common research subject for developmental biology, retinal physiology, cell biology, and other investigations, has been limited by lack of a robust gene knockout or knockdown technology. Here we describe manipulation of the X. laevis genome using CRISPR/Cas9 to model the human disorder retinitis pigmentosa, and to introduce point mutations or exogenous DNA sequences. We introduced and characterized in-frame and out-of-frame insertions and deletions in three genes encoding rhodopsin by co-injection of Cas9 mRNA, eGFP mRNA, and single guide RNAs into fertilized eggs. Deletions were characterized by direct sequencing and cloning; phenotypes were assessed by assays of rod opsin in retinal extracts, and confocal microscopy of cryosectioned and immunolabeled contralateral eyes. We obtained germline transmission of editing to F1 offspring. In-frame deletions frequently caused dominant retinal degeneration associated with rhodopsin biosynthesis defects, while frameshift phenotypes were consistent with knockout. We inserted eGFP or point mutations into rhodopsin genes by co-injection of repair fragments with homology to the Cas9 target sites. Our techniques can produce high frequency gene editing in X. laevis, permitting analysis in the F0 generation, and advancing the utility of X. laevis as a subject for biological research and disease modeling.

The African clawed frog Xenopus laevis is an amphibian species often used in laboratory research due to a number of desirable properties, including induction of breeding by hormone injection, minimal housing requirements, and no requirement for live food1,2. It is frequently used in studies of developmental biology, cell biology, retinal research, electrophysiology, and numerous other applications. In our laboratory we make use of X. laevis in cell biology studies of retinal photoreceptors3–6, including modeling of the human disorder retinitis pigmentosa7–11, due to the relative ease with which X. laevis can be genetically modified by transgene insertion. Non-chimeric transgenic X. laevis can be generated using the method of Kroll and Amaya12 or other methodologies13–15 at very high rates. F0 animals can be analyzed rather than waiting for F1 offspring, allowing very short experimental timeframes16.

However, robust knockout and knockdown technologies for X. laevis have not been previously available. Although morpholinos can be used in early developmental stages17–19 it is difficult to discriminate non-specific effects20. X. laevis do not have robust RNAi responses21, and techniques analogous to standard mouse knockout procedures requiring embryonic stem cells are not feasible due to lack of cell lines. A further complication is the allotetraploid nature of the X. laevis genome22–24.

Recent development of the CRISPR/Cas9 gene editing system should allow gene modification and knockout in virtually any species, including X. laevis25. This two component system consists of a DNA-cleaving enzyme
(Cas9) complexed with an RNA that guides Cas9 to a specific DNA sequence (single guide RNA or sgRNA)26–28. Cleavage triggers the non-homologous end-joining (NHEJ) DNA repair mechanism, frequently resulting in insertion or deletion of short DNA sequences (indels). No other endogenous factors are required. Indels in early exons can create frame-shift mutations that trigger nonsense-mediated decay, acting as loss-of-function mutations or “knockouts”, or in-frame deletions and insertions that result in protein instability. This technology has previously been successfully applied to generate knockouts of tyrosinase in X. laevis and the related diploid species Xenopus tropicalis29, 30 to generate F0 albino animals. Additionally, breaks in genomic DNA caused by Cas9 can trigger homology-directed repair (HDR) which can be used to introduce DNA sequences at specific sites via homologous recombination31, 32.

Here we report the successful application of CRISPR/Cas9 technology to editing of the X. laevis genome. As a target, we chose the genes encoding X. laevis rhodopsin (i.e. rod opsin). Rhodopsin is expressed at very high levels exclusively in retinal rod photoreceptors, and is a focus of our research program. Based on previous reports of rhodopsin knockouts in mice33, 34, loss-of-function rhodopsin mutations in humans, and missense rhodopsin mutations in humans and a variety of transgenic animals, we anticipated that CRISPR/Cas9 based gene editing of the rhodopsin genes would cause non-lethal phenotypes in X. laevis. We anticipated that loss-of-function mutations would cause reduced rhodopsin expression, while mutations that alter the amino acid sequence may cause aggressive RD, and that these phenotypes would be detectable by rhodopsin immunoassays and confocal microscopy.

By using this technology to create genomic DNA breakpoints and indel mutations, we were able to generate rhodopsin knockout and gain of function phenotypes in X. laevis tadpoles that model the human conditions of recessive and dominant retinitis pigmentosa. Furthermore, we were able to use the technology to selectively edit specific alleles, and to introduce foreign DNA sequences and point mutations by homologous recombination. Genome editing occurred efficiently in germline cells, allowing F1 generation tadpoles. These techniques add new versatility to X. laevis as a research subject, and are likely to be highly useful for cell and developmental biologists, including those conducting research on rhodopsin function and rhodopsin gene regulation, and retinal disease mechanisms.

Materials and Methods

In vitro transcription of mRNA and sgRNA, and sgRNA design. Cas9 mRNA was in vitro transcribed from pMLM3613 (A gift from Keith Joung - Addgene plasmid #42251), linearized using Pmel, with T7 mMessage mMachine Ultra kit (Ambion) or HiScribe ARCA kit (NEB) according to the manufacturer’s instructions and subsequently purified using the RNeasy kit (Qiagen). EGFP mRNA was in vitro transcribed from a linear plasmid template using the T7 mMessage mMachine Ultra kit (Ambion) according to the manufacturer’s instructions and subsequently purified using the RNeasy kit (Qiagen).

sgRNA target sites were identified by scanning published X. laevis rhodopsin sequences using the online ZifiT target finding tool (http://zifit.partners.org/ZiFiT/). Three sgRNAs were designed and tested: rhosg3 (targets exon 1 of rho.2.L), rhosg1 (targets exon 1 of all X. laevis rhodopsin genes), and rhosg4 (targets the final exon 5 of all X. laevis rhodopsin genes). See Supplementary information Fig. 1 for details.

Oligonucleotides corresponding to these sgRNA targeting sequences were cloned into the BbsI site of pDR274 (A gift from Keith Joung - Addgene plasmid #42250). This plasmid contains a sgRNA scaffold. The pDR274 derivatives were linearized with DraI and used as templates for in vitro transcription of sgRNA using the MAXIscript in vitro transcription kit (Ambion) and subsequently purified using the RNeasy kit (Qiagen). Two individual reactions were then combined and concentrated by ethanol precipitation. pMLM3613 and pDR274 were previously used for generating Cas9 mRNA and sgRNAs for use in zebrafish genome editing35.

Final products were evaluated for size and purity by agarose gel electrophoresis, and quantified by absorbance at 260 nm with NanoDrop 2000c spectrophotometer (Thermo Scientific).

Microinjections. Ovulation was induced in female X. laevis by injection of human chorionic gonadotropin, and testes were isolated from male X. laevis. One-half of one testis was macerated in 250 µL 0.1X MMR and then added to eggs manually expelled into a petri dish. After a 2-minute incubation, the eggs were covered in 0.1X MMR and incubated a further 20 minutes. The fertilized eggs were then dejellied in 2% cysteine pH 8.0, 1X MMR, and arranged in a monolayer covered with 0.4X MMR, 6% Ficoll. RNAs were combined, centrifuged at 13,000 RPM for 1 minute prior to loading into a pulled glass micropipette with a 20–25 µm bore which was then connected to a Hamilton syringe pump set to deliver 36 µL per hour, and mounted in a micromanipulator. Embryos were injected for 1 second equating to 10 nL of RNA. After microinjection, embryos were transferred to 18 °C for approximately 2.5 hours until the four-cell stage, at which point embryos that exhibited appropriate signs of cell division were transferred to 0.1X MMR + 6% Ficoll + 10µg/mL gentamicin and stored overnight at 18 °C. Embryos were transferred to 0.1X MMR 24 hrs post-fertilization. Embryos were screened for EGFP fluorescence using an epifluorescence-equipped Leica MZ16F dissecting microscope.

PCR products/cloning of PCR products. For analysis of indels, approximately 300 bp of sequence around the rhog1 and rhog3 target-sites were amplified by PCR using primer sequences: CATGTGGGATCACAGGCCCTC and CAGGAGTGTCAAGGGGTG for rhodopsin chromosome 4L paralogs rho.L and rho.2.L, and primer sequences: CACAGAAGGGATTCTTTCTAG and CAGGAAATGATCATTAAAGGGTG for the rho.S homolog. Two rho.S forward primers were used due to the presence of two alleles in database files.

Direct sequencing of PCR products and sequencing of clones. PCR products were directly sequenced with the respective forward primers by the Sanger dye-termination method after exonuclease I-shrimp alkaline phosphatase treatment36. PCR products were ligated into EcoRV-linearized pBluescript-SKI+ by a directional Gibson assembly reaction37, and used to transform E. coli, allowing isolation of individual genomic
sequence clones. For cloning, we utilized loci-specific primers with sequences identical to those above, with additional 24 base pair "tails" with homology to PBS-SKII+ required for the directional Gibson assembly reaction. Forward primers incorporated the 5′ homology tail sequence GTCCACCGGTATCGAATAAGCTTGAT, while reverse primers incorporated the 5′ homology tail sequence TCCCCGGGCTGCAGGAATTCGAT. Overnight cultures derived from individual colonies were mini-prepped and sequenced by the Sanger dye-termination method using M13 universal primer.

**Determining extent of genomic editing.** To provide a measure of the extent of genome editing that could be compared between samples, we developed an algorithm to summarize the deviation from wildtype (WT) sequence at each nucleotide position of a direct sequencing reaction read as a "sequence fidelity score". Sanger sequencing data output files (generated as *abi* files by the ABI Prizm Sanger sequencing software) were uploaded to the Life Technologies ab1PeakReporter online tool (https://apps.thermofisher.com/ab1peakreporter7), which extracts information regarding primary (most probable) and secondary (most probable) base calls (largely based on the highest and second-highest peaks at each nucleotide position) into a file readable by Microsoft Excel (http://tools.thermofisher.com/content/sfs/brochures/seq-quantification-app-note.pdf). We identified the primary and secondary peak base call for each nucleotide position in sequencing reads from experimental samples using the ab1PeakReporter tool, and assigned a numerical value for each position of the experimental sequencing read based on comparison to the primary base call in an aligned control WT sequencing read. A perfect match of the primary base call with WT was assigned a score of 1, and a mismatched primary base but matched secondary base was assigned a score of 0.25. Complete mismatch was assigned a score of zero. In addition, partial matches with ambiguous base calls such as "Y" and "R", as defined by the International Union of Pure and Applied Chemistry were assigned intermediate scores. The complete scoring formula is shown in Supplemental Table 1. For comparison plots, the scores were plotted as moving averages over 10 bases.

**Dot blot assay for rod opsin.** Individual tadpole eyes were solubilized, and aliquots were diluted and applied to Immobilon P membranes (Millipore) as previously described. Blots were probed with anti-rhodopsin antibody B630N and IR-dye800 secondary antibody (LI-COR), and imaged and quantified using a LI-COR Odyssey imaging system as previously described.

**Confocal microscopy.** Eyes were fixed overnight at 4 °C in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4, and then transferred to 20% sucrose in phosphate buffer pH 7.4 for one hour before embedding and quick-freezing in OCT medium (TissueTek). Eyes were fixed overnight at 4 °C in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4, and then transferred to 20% sucrose in phosphate buffer pH 7.4. Cryosections were obtained, embedded in Eponate12 resin, and processed for electron microscopy using procedures identical to those previously described.

**Electron microscopy.** Animals were fixed in 1% glutaraldehyde, 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4. Cryosections were obtained, embedded in Eponate12 resin, and processed for electron microscopy using procedures identical to those previously described.

**HDR procedures.** HDR repair fragments were ligated into EcoRV-linearized pBluescript-SKII+ by Gibson assembly. *Rhodopsin* fragments were amplified from genomic DNA using primers based on the *rhodopsin* gene sequence published by Batni et al.**49** (corresponding to rho.2.L), and eGFP sequences were amplified from eGFP-C1 (Clontech). The sgRNA target-sites were subsequently mutagenized and the M13F epitope inserted using the quickchange mutagenesis kit (Agilent). Constructs were purified using the Miniprep Kit (Qiagen), linearized at Smal, and concentrated using QIAEX II bead purification kit (Qiagen). The eyes of eGFP-HDR animals were screened for fluorescence using an epifluorescence-equipped dissecting microscope.

**Animal care.** Experimental procedures were approved by the UBC Animal Care Committee and were performed in accordance with Canadian Council on Animal Care guidelines and regulations.

**Results**

**Rhodopsin gene organization in *X. laevis.*** We searched genomic DNA sequence data from the *X. laevis* genome project available at Xenbase for sequences encoding rod opsins. Based on blast searches using previously published *X. laevis* rhodopsin gene sequence, we identified three gene sequences encoding rod opsins, i.e. rhodopsin, rho.S (XB-GENE-17342665) on chromosome 4S, and two paralogous gene sequences, rho.L (XB-GENE-966893) and rho.2.L (XB-GENE-18034123), corresponding to the sequence identified by Batni et al. located within a 17 kb region on chromosome 4 L. These gene sequences have highly similar coding regions (Supplementary Figure 1), although intron regions have diverged considerably. Matching EST sequences present...
in the Sanger Centre databases indicate that all three genes are transcriptionally active. All differences between paralogs and homeologs in coding regions are either silent or result in conservative amino acid changes, suggesting all three genes encode functional rhodopsins.

**Injected Cas9 mRNA is not significantly toxic to in-vitro fertilized embryos.** Based on Cas9 mRNA quantities utilized by Nakayama et al. for genome editing in *X. tropicalis* for genome editing in *X. tropicalis* for genome editing in *X. tropicalis*, we compared the survival rates of *in vitro* fertilized embryos injected with 14 ng, 5 ng, 1.5 ng, 0.5 ng, or 0.15 ng of Cas9 mRNA at the single-cell stage. 700 pg of eGFP mRNA was co-injected as a reporter for successful Cas9 mRNA delivery. Toxicity was not evident in any of the injection groups, as survival rates of GFP-expressing embryos were not different from uninjected embryos. At 14 days post-fertilization (dpf) (Nieuwkoop and Faber developmental stage 48), morphology of tadpoles derived from injected embryos was not different than morphology of tadpoles derived from wildtype (WT) uninjected embryos (not shown).

**Injection of Cas9 mRNA + guide RNA induces retinal degeneration phenotypes.** We designed single guide RNAs (sgRNAs) that target the first exon of rho.S, rho.L, and rho.2.L and injected varying concentrations of Cas9 mRNA and sgRNA, along with eGFP mRNA, into fertilized *X. laevis* eggs. Non-fluorescent, weakly or partly fluorescent embryos were eliminated from the analysis at 1 dpf. At 14 dpf, we analyzed the resulting tadpole phenotypes by anti-rod opsin dot blot assay of total eye protein extracts and confocal microscopy of contralateral eyes as previously described. Our initial experiments were conducted before we were aware of the presence of the rho.2.L paralog, which we identified after the release of the *X. laevis* genome (http://www.nature.com/nature/journal/v538/n7625/abs/nature19840.html). These experiments utilized rhosg3, an sgRNA whose target sequence is an exact match only with rho.L. We noted increasingly severe phenotypes of reduced rod opsin protein levels (Fig. 1A) and RD (Fig. 1B) on injection of higher concentrations of both sgRNA and Cas9 mRNA (Fig. 1), consistent with disruption of *rhodopsin* genes. However, no animals with complete absence of rod opsin were generated.

**rhosg1 generates more severe phenotypes than rhosg3.** rho.S and rho.2.L are not targeted by the sgRNA rhosg3 (used in the experiment shown in Fig. 1) due to the presence of two mismatched bases at positions 1 and 6 in the protospeacer. We therefore compared the effects of rhosg3 with those of a second sgRNA (rhosg1) that targets all gene variants identified (Supplementary Figure 1), as well as a control non-targeting sgRNA (rhosgN, the reversed sequence of rhosg3). We observed substantially greater reduction in total rod opsin in 14 dpf animals on co-injection of Cas9 mRNA + rhosg1 in comparison to Cas9 mRNA + rhosg3 (Fig. 2). Again, complete absence of expression was not observed, but total rod opsin levels averaged 7% of WT. In contrast, minimal effects on total rod opsin were observed on co-injection of Cas9 mRNA + rhosgN.

**Indels are present in the genomic DNA of F0 animals.** Studies utilizing NHEJ-mediated production of indels typically employ endonuclease-based assays as a rapid means of detecting genome editing, in which PCR products are digested with endonucleases that target mismatched sequences. Due to the presence of the paralogous rho.L and rho.2.L sequences in our samples that were not distinguished by PCR primers, we found that these assays were unreliable and typically showed digestion of PCR products in WT samples (not shown). Allelic variants in our non-inbred populations of *X. laevis* could also contribute to this effect. Therefore, we adopted an alternate method based on Sanger dye-termination sequencing of PCR products derived from the targeted *rhodopsin* sequences. Whereas WT trace reads typically contain minimal background noise, we found that trace reads derived from animals exhibiting severe phenotypes on rod opsin dot blot assays or confocal microscopy had high levels of noise just prior to and following the predicted cleavage sites (Fig. 3), consistent with a template containing multiple similar sequences of different lengths. We developed a method for comparing samples in which we graphed the moving average of a sequence fidelity score calculated from sequence data files (see methods section for details). This provided a useful means of comparing the extent of genomic DNA editing between samples (Fig. 3C–F). This analysis demonstrated extensive editing of genomic DNA, and also indicated that the majority of indels are small, as the sequence files generally did not show increased miscalling > 10 bp prior to the cleavage site.

**Genome editing occurs as early as 1dpf.** As a means of determining the approximate timeframe of genomic editing in our embryos, we analyzed genomic DNA from embryos injected with Cas9 mRNA + rhosg1 or Cas9 mRNA + rhosg3 at both 14 dpf (developmental stage 48) and 1dpf (developmental stage 12–15) (Nieuwkoop and Faber, 1994). At both developmental stages, many embryos showed extensive editing observed in direct sequencing trace reads (Fig. 3C–F), indicating that editing of the *rhodopsin* genes can occur prior to eye development, at a stage where these genes are not transcriptionally active. Transcriptionally inactive genes may be located in heterochromatin, which Cas9 samples less frequently and scans more slowly, potentially limiting development, at a stage where these genes are not transcriptionally active. Transcriptionally inactive genes may not prevent robust editing of the *X. laevis rhodopsin* genes.

**Confirmation editing occurs as early as 1dpf.** To examine individual sequences of the indels generated by these procedures, we cloned PCR products and determined DNA sequences from individual clones. In 1 dpf embryos and 14 dpf tadpoles generated via injection of Cas9 mRNA and rhosg1, we observed indels in all three *rhodopsin* genes (Fig. 4A–D). Small deletions of < 20 bp were most commonly observed, but large deletions, including a deletion greater than 100 bp, and small insertions, were also observed, as well as simultaneous deletions and insertions, consistent with results reported for NHEJ-based mutagenesis in other systems and for editing of *X. laevis tyrosinase* genes. We also noted that identical
sequences were sometimes returned in our small samples of clones, suggesting that editing can occur early in development when the number of cells per embryo is low (Fig. 4A). However, in other cases identical clones were not observed, indicating that the timing of editing may be somewhat variable (Fig. 4B), and that the F0 animals are genetic mosaics. Further characterization of indels by techniques such as high-throughput sequencing of multiple F0 embryos would be required to accurately assess the developmental timeframe of genomic editing.

**sgRNAs do not induce indels in mismatched alleles.** In 1 dpf embryos and 14 dpf tadpoles generated via injection of Cas9 mRNA and rhosg3, we did not observe significant editing of mismatched \( \text{rho.S} \) and \( \text{rho.L} \) sequences (Fig. 4E–H). In conjunction with the low levels of toxicity observed in animals injected with Cas9 mRNA alone or Cas9 mRNA + non-targeting rhosgN, this suggests that off-target effects due to non-specific cleavage are likely to be minimal. This result also demonstrates that in an outbred animal model such as \( X. \text{laevis} \), it may be possible to selectively edit allelic variants in order to specifically generate heterozygous knockouts (potentially extremely useful in cases where homozygous knockout is lethal).

**Germline transmission of edited rhodopsin genes.** We examined F1 progeny of matings of \( X. \text{laevis} \) derived from embryos injected with rhosg3 or rhosg1 and Cas9 mRNA with either wildtype \( X. \text{laevis} \) or similarly genetically modified animals using techniques similar to those described above. Animals were selected for breeding based on editing observed in genomic DNA isolated from blood samples using analysis similar to Fig. 3.
Germline transmission of indels and phenotypes of F1 animals. Dot blot analysis of total rod opsin levels showed reduced rod opsin in retinal extracts (Fig. 5), and indels were identified by DNA sequencing, indicating successful modification of germline cells in the F0 parents.

**Figure 2.** Relative to guide RNA rhosg3, rhosg1 causes greater reductions in rod opsin and greater rod photoreceptor loss. 6 ng of Cas9 mRNA and 2 ng of sgRNA were co-injected. (A) Rod opsin levels assayed in individual eyes by dot blot assay at 14 dpf. Each data point represents a different animal. P values are for Tukey multiple comparisons test for comparisons with WT group. P (ANOVA) = 2.9 × 10⁻⁸ (B) Phenotypes assessed by confocal microscopy. Green: anti-rhodopsin (B630N). Red: wheat germ agglutinin. Blue: Hoechst 33342. RPE: retinal pigment epithelium. OS: outer segments. IS: inner segments. ONL: outer nuclear layer. INL: inner nuclear layer. Bar = 50 µm.
in both rho.L alleles; these also showed no obvious signs of rod cell loss, although rod outer segments appeared shorter (Fig. 5I).

Based on these results, it is likely that the phenotypes we observed in genetically mosaic F0 animals (Figs 1 and 2) are due to a combination of loss-of-function frameshifting and gain-of-function frame-conserving mutations, modeling equivalent effects of loss-of-function and gain-of-function rhodopsin mutations responsible for recessive and dominant forms of the human disorder retinitis pigmentosa.

Phenotypes of rhodopsin knockouts (electron microscopy). Using transmission electron microscopy (Fig. 6), we examined rod photoreceptors of F1 animals with loss-of-function mutations in one allele of rho.L caused by insertion of a single base pair in exon 1 induced by rhosg3. Ultrastructurally, the rod photoreceptors were comparable to wildtype, with regularly spaced and well-organized disk membranes, and closely apposed disk rim and plasma membrane regions, consistent with previous findings of relatively mild phenotypes in heterozygous rhodopsin knockout mice.

HDR-mediated insertion of a foreign eGFP sequence into rhodopsin. To determine whether we could use genome editing by Cas9 mRNA and sgRNAs to induce insertion of foreign DNA sequences by homology-directed repair (HDR) as reported for other systems\cite{2, 6, 49}, we generated a third sgRNA (rhosg4) that targets the fifth exon of all three rhodopsin genes, as well as a repair template constructed with approximately 1200 bp of homology to rho.2.L around the rhosg4 predicted cut-site, and encoding eGFP at a position in the rhodopsin peptide sequence previously demonstrated to generate a functional rhodopsin-GFP fusion protein\cite{50}. The homology sequence on the repair template also encoded two silent mutations in the rhosg4 recognition sequence to prevent re-cleavage by Cas9 after integration (For complete sequence see Supplemental Figure 2).

Injections of Cas9 mRNA and rhosg4 were conducted as described above, with the additional inclusion of the repair template, and eyes of injected tadpoles were screened by fluorescence microscopy during the second week of development. To avoid having eGFP signals originating from two sources, no eGFP mRNA was co-injected, and all injected embryos were screened for the predicted phenotype. eGFP fluorescence was detected in the eyes of two animals out of 456 screened. These were subsequently analyzed by confocal microscopy. Interestingly,
both animals showed eGFP expression in both eyes. The eGFP fluorescence was confined to a subset of rod photoreceptors, was highly expressed in outer segments, and was not expressed in other cell types (Fig. 7A–C). The localization was consistent with results previously reported for rhodopsin-GFP fusion proteins expressed in X. laevis rods50–52. However, these retinas also exhibited significant RD, and rod cells had abnormal morphologies regardless of whether they expressed the fusion, suggesting that homology-directed repair was incomplete. It is possible that this RD reduced the apparent efficiency of the procedure by eliminating fluorescent rods. The RD is likely due to the fact that rhosg4 targets the last exon of all three rhodopsin genes, resulting in gene editing in the absence of nonsense mediated decay and high rates of dominant disease-causing mutations. In agreement, similar retinal degeneration was also observed in retinas of animals edited with rhosg4 in the absence of HDR repair template (Fig. 7A). PCR amplification and Sanger sequencing of the targeted regions of the three rhodopsin genes confirmed that eGFP integrated exclusively into rho.2.L as predicted, and that rhosg4 also generated indels in the rho.S and rho.L genes (not shown).

**Figure 4.** Characterization of indels by sequencing genomic DNA clones: (A–H) Sequences obtained from individual pBluescript-SKII+ clones of PCR products derived from genomic DNA isolated from F0 embryos at either 1 dpf or 14 dpf (as indicated) edited with Cas9 mRNA + rhosg1 or rhosg3 (as indicated). The reverse complement sequence of the guide RNA is shown above the individual genomic DNA sequences in blue. The targeted sequences are also shown in blue. Mismatches with the guide RNA are shown in magenta. Insertions are noted in green. The protospacer adjacent motif (PAM) sequence is shown in red. Bases that are diagnostic of rho.L vs. rho.2.L are shown in orange. The number at the beginning of each sequence corresponds to sample numbers for direct sequencing results shown in Fig. 3.

**HDR-mediated insertion of a point mutation into rhodopsin.** Similarly, we investigated the use of HDR to introduce targeted point mutations, using rhosg1 and a repair template containing approximately 1500 bp of homology to rho.2.L flanking the rhosg1 targeting site, and encoding a 2 bp change designed to insert the single
amino acid change met13→phe, which was previously demonstrated to confer reactivity to the anti-mammalian rhodopsin antibody 2B2. The repair template similarly encoded two silent mutations designed to eliminate re-cleavage by Cas9 and rhosg1 (Supplemental Figure 2).

We examined retinas of eGFP positive animals using confocal microscopy and 2B2 labeling. Forty-one eyes were cryosectioned, and three were found to contain small numbers of 2B2-positive rods (Fig. 7D,E), while the other eyes did not. The majority of the eyes examined exhibited severe RD, which potentially eliminated 2B2-positive rods, possibly reducing the apparent efficiency of the procedure. One eye containing 2B2-positive rods did not exhibit any RD (Fig. 7D,E); potentially fewer editing events in this animal allowed the genetically modified rods to survive for positive identification.

Discussion
We have demonstrated manipulation of the genes encoding rhodopsin in the allotetraploid X. laevis genome using CRISPR/Cas9 technology, including the generation of knockout and dominant alleles, and targeted insertions.
These modifications occur in somatic cells with high efficiency early in development, permitting analysis in F0 animals, and also occur in germline cells, with high efficiency transmission to F1 offspring.

Due to the allotetraploid nature of the *X. laevis* genome, two homeologs are present for most gene products represented by a single gene in diploid species such as humans and mice, and three genes are present for *rhodopsin*. However, based on our experience with *rho.L* and *rho.S*, it is possible to design sgRNAs that will target both *X. laevis* homeologs (Fig. 2), and in the case of *rhodopsin*, a third paralogous gene sequence *rho.2.L*. It is similarly possible to design sgRNAs that will target a single gene (Figs 1 and 4), allowing a researcher to selectively manipulate one or both homeologs, a potentially valuable tool for studying the function of genes that produce lethal phenotypes on complete knockout. Thus, the allotetraploid *X. laevis* genome poses some experimental difficulties relative to genetic manipulation of other species, while also introducing additional versatility.

By injection of mRNA encoding Cas9 and sgRNAs targeting a gene of interest, we were able to generate phenotypes in the majority of F0 animals (Figs 1 and 2). Thus, we are able to perform genetic manipulation experiments in relatively short timeframes, without waiting for F1 offspring. This is similar to paradigms we have used with transgenic *X. laevis*, in which large numbers of F0 transgenic animals are analyzed to obtain insight into gene function65–7, 16, 54. The techniques described here greatly increase the utility of *X. laevis* for experimental paradigms such as disease modeling and investigation of gene function. Additionally, we observed efficient transmission of genetic manipulations to F1 offspring (Fig. 5), thus, interesting experimental results obtained in F0 animals can be confirmed or further characterized at a later date in F1 offspring (Figs 1, 5 and 6).

We noted that in-frame deletions in the *X. laevis rhodopsin* genes can cause dominant phenotypes distinct from the loss-of-function obtained with out-of-frame deletions, complicating the analysis of genetically mosaic F0 animals. This is likely due to the fact that rhodopsin is expressed at very high (millimolar) levels in rod outer segment disks56, such that defects in biosynthesis and trafficking can cause ER stress and cell death8, 11, 47, 57–59. These phenotypes are similar to those observed with missense mutations, and likely model forms of the human disorder retinitis pigmentosa associated with rhodopsin instability11, 16, 47. Related phenotypes are less likely to occur with manipulation of genes that are expressed at low levels, where misfolding is unlikely to overload quality control processes and is more likely to cause a variant of loss of function60. However, it is possible that unanticipated dominant phenotypes could occur with any gene, as well as relatively innocuous outcomes such as the single and dual amino acid deletions we detected (Fig. 5B,C). Moreover, if gain of function phenotypes are not desired, is likely that phenotypes associated with in-frame deletions could be minimized by injection of multiple sgRNAs targeting multiple exons, increasing the likelihood of obtaining at least one frame-shifting deletion and consequent nonsense-mediated decay. In-frame deletions are also less likely to occur when gene copy numbers are smaller; the presence of six rhodopsin alleles decreases the odds of complete knockout in any given cell due to increased likelihood of in-frame deletions and decreased likelihood of complete editing of all genes. Our results demonstrate that careful examination of the resulting phenotypes is warranted in any experiment of this type.

The phenotypes we observed in animals heterozygous and homozygous for loss-of-function mutations in *rho.2.L* are consistent with phenotypes reported in *rhodopsin* knockout mice, and human carriers of *rhodopsin* mutations responsible for autosomal recessive retinitis pigmentosa53, 54, 61. In particular, we observed reduced rod opsin content of retinas, without extensive cell death of rod photoreceptors, and rod outer segments with well-ordered and regularly spaced disks. As in-frame mutations in all three *rhodopsin* genes were associated with RD, our results demonstrate that all three genes are expressed at significant levels. More detailed analysis of F1

Figure 6. Electron microscopy of rod photoreceptors with loss of function mutations in one *rho.L* allele: (A) images of rods with a 1 bp insertion in one *rho.L* allele induced by rhosg3. (B) Comparable images from WT rods. Outer segment (OS) disks are densely packed at both the rim and lamellar (LAM) regions. Disk rims are closely apposed to the plasma membrane (PM). No significant abnormalities were identifiable. IS: inner segment. Bar = 400 nm (left) 200 nm (center) or 100 nm (right).
offspring will be necessary to establish the exact contributions of each gene, and to determine whether the three genes are expressed consistently throughout development. In addition to modeling the human disorder recessive retinitis pigmentosa, knockout animals will be useful for future examinations of the role of rhodopsin in regulating rod outer segment disk membrane synthesis. Interestingly, we did not observe dramatic alterations in outer segment diameter such as those reported by Makino et al. in mice 62–64, although rod outer segments did appear shorter (Fig. 5H,I).

In addition to introducing simple insertions and deletions via NHEJ, we also attempted to introduce specific point mutations and large coding sequences into the \( \text{rho.L} \) genes via homology directed repair (HDR), including both a point mutation that introduces an antibody epitope and a large sequence encoding GFP, both of which are well characterized from previous use in rhodopsin transgenes 47, 50, 52, 65. Both types of gene modification were successful, indicating that these techniques could be used to introduce sequences for modeling disease or structure/function studies. However, the desired phenotypes (antibody reactivity, green fluorescence) were not obtained efficiently, although it is possible that the aggressive RD induced by the sgRNAs prevented detection of antibody reactivity or green fluorescence in a significant subset of animals. Thus, unlike analysis of indel-generated phenotypes, it would likely be prohibitively difficult to utilize these approaches as described for routine analysis in F0 animals. However, HDR approaches in F0 animals might be feasible after further optimization. For example, it is likely that HDR efficiency could be improved by treating injected embryos with drugs such as SCR7 that inhibit NHEJ 66, 67. In addition, targeting a single gene or allele is likely preferable if NHEJ frequently results in dominant cell death phenotypes. Future optimization of HDR in this system would benefit from a sgRNA that targets only

**Figure 7.** HDR mediated gene alterations assessed by confocal microscopy: (A) RD in an animal edited using sgRNA rhosg4 (B,C,C’) images derived from an animal in which rhosg4 was used to direct targeted insertion of eGFP into \( \text{rho.L} \). A number of eGFP-positive rods are present, while other cells of the retina and lens do not show eGFP expression. Significant RD is present (D,E) images derived from an animal with targeted mutation of residue M13→F in \( \text{rho.L} \), and stained with anti-mammalian rhodopsin (2B2). There is no identifiable RD. (A–C) Green: eGFP. (D,E) green: anti-mammalian rhodopsin (2B2). (A,B) Red: anti-rod transducin. C–E: Red: wheat germ agglutinin. (A–E) Blue: Hoechst 33342. OS: outer segments. IS: inner segments. ONL: outer nuclear layer. INL: inner nuclear layer. GCL: ganglion cell layer. (A,B,D) Bar = 200 μm. (C) Bar = 50 μm. (C’) Bar = 10 μm. (E) Bar = 20 μm. Panels C and C’ are confocal projections derived from 10 confocal sections.
a single rhodopsin gene in order to reduce the co-occurrence of retinal degeneration. In addition, the use of a shorter single stranded DNA oligonucleotide repair template may improve the efficiency of HDR for introduction of short sequences such as the M13F epitope.

X. laevis is an animal frequently used in laboratory investigations, particularly in the fields of developmental biology and vision research. X. laevis are valued for the relative ease with which they can be bred, and the rapid ex-vivo development of the resulting embryos. Transgene-based genome manipulation strategies have greatly increased the utility of this species as an experimental animal. However, the lack of a robust gene knockout or knockdown strategy was a significant limitation. Our description of efficient knockout strategies using CRISPR/Cas9 will further increase the experimental utility of X. laevis in studies examining gene function, including studies of rhodopsin. Shared genomics, cell biology, anatomy and physiology between human and Xenopus species, along with the increased accessibility of this model through transgenesis and genome editing procedures, make Xenopus laevis an exciting and promising candidate for human disease modeling.

References
1. Pearl, E. J., Grainger, R. M., Guille, M. & Horb, M. E. Development of xenopus resource centers: The national xenopus resource and the european xenopus resource center. *genesis* 50, 155–163 (2012).
2. Callory, E. M. There's more than one frog in the pond: A survey of the Amphibia and their contributions to developmental biology. *Semin. Cell Dev. Biol.* 17, 80–92 (2006).
3. Tam, B. M., Moritz, O. L., Hurd, L. B. & Papernast, D. S. Identification of an outer segment targeting signal in the COOH terminus of rhodopsin using transgenic Xenopus laevis. *J Cell Biol* 151, 1369–1380 (2000).
4. Tam, B. M., Moritz, O. L. & Papernast, D. S. The C terminus of peripherin/rds participates in rod outer segment targeting and alignment of disk incurses. *Mol Biol Cell* 15, 2027–2037 (2004).
5. Moritz, O. L. et al. Mutant rab8 Impairs docking and fusion of rhodopsin-bearing post-Golgi membranes and causes cell death of transgenic Xenopus rods. *Mol Biol Cell* 12, 2341–2351 (2001).
6. Tam, B. M. & Moritz, O. L. The role of rhodopsin glycosylation in protein folding, trafficking, and light-sensitive retinal degeneration. *J Neurosci* 29, 15145–15154 (2009).
7. Tam, B. M., Noorwez, S. M., Kaushal, S., Kono, M. & Moritz, O. L. Photoactivation-Induced Instability of Rhodopsin Mutants T4K and T17M in Rod Outer Segments Underlies Retinal Degeneration in X. laevis Transgenic Models of Retinitis Pigmentosa. *J. Neurosci.* 34, 13336–48 (2014).
8. Tam, B. M., Qazalbash, A., Lee, H. C. & Moritz, O. L. The dependence of retinal degeneration caused by the rhodopsin P23H mutation on light exposure and vitamin a deprivation. *Invest Ophthalmol Vis Sci* 51, 1332–1334 (2010).
9. Tam, B. M., Lai, C. C.-L., Zong, Z. & Moritz, O. L. Generation of transgenic X. laevis models of retinal degeneration. *Methods Mol. Biol.* 935, 113–25 (2013).
10. Nutt, S. L., Bronchain, O. J., Hartley, K. O. & Amaya, E. Comparison of morpholino based translational inhibition during the development of Xenopus laevis and Xenopus tropicalis. *Cell Biol Cell Biol.* 3, 63 (2009).
11. Tam, B. M., Lai, C. C.-L., Zong, Z. & Moritz, O. L. Generation of transgenic X. laevis models of retinal degeneration. *Methods Mol. Biol.* 935, 113–25 (2013).
12. Ogino, H., McConnell, W. B. & Grainger, R. M. High-throughput transgenesis in Xenopus using I-SceI meganuclease. *Nat Protoc* 1, 1703–1710 (2006).
13. Schulte-Merker, S. & Stainier, D. Y. R. Out with the old, in with the new: reassessing morpholino knockdowns in light of genome editing technology. *Development* 141 (2014).
14. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
15. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
16. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
17. Tandon, P., Conlon, E., Furlow, J. D. & Horb, M. E. Expanding the genetic toolkit in Xenopus: Approaches and opportunities for human disease modeling. *Dev. Biol. doi:10.1016/j.ydbio.2016.04.009* (2016).
18. Hsu, P. D., Lander, E. S. & Zhang, F. Development and Applications of CRISPR-Cas9 for Genome Engineering. *Cell* 157, 1262–1278 (2014).
19. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
20. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
21. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
22. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
23. Tandon, P., Conlon, E., Furlow, J. D. & Horb, M. E. Expanding the genetic toolkit in Xenopus: Approaches and opportunities for human disease modeling. *Dev. Biol. doi:10.1016/j.ydbio.2016.04.009* (2016).
24. Hsu, P. D., Lander, E. S. & Zhang, F. Development and Applications of CRISPR-Cas9 for Genome Engineering. *Cell* 157, 1262–1278 (2014).
25. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
26. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
27. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
28. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
29. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
30. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
31. Chien, C.-M., Chiu, S.-L., Shen, W. & Cline, H. T. Co-expression of Argonaute2 Enhances Short Hairpin RNA-induced RNA Interference in Xenopus CNS Neurons In Vivo. *Front. Neurosci.* 3, 63 (2009).
32. Matsuda, Y. et al. A New Nomenclature of Xenopus laevis Chromosomes Based on the Phylogenetic Relationship to Silurana/ Xenopus tropicalis. *Cytogenet. Genome Res.* 145, 187–91 (2015).
33. Tandon, P., Conlon, E., Furlow, J. D. & Horb, M. E. Expanding the genetic toolkit in Xenopus: Approaches and opportunities for human disease modeling. *Dev. Biol. doi:10.1016/j.ydbio.2016.04.009* (2016).
34. Lem, J. et al. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc Natl Acad Sci USA 96, 736–741 (1999).
35. Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227–9 (2013).
36. Bell, J. A simple way to treat PCR products prior to sequencing using ExoSAP-IT. Biotechniques 44, 834 (2008).
37. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).
38. Tam, B. M. et al. Preparation of Xenopus laevis retinal cryosections for electron microscopy. Exp. Eye Res. 136, 86–90 (2015).
39. Batmi, S., Scalzaetti, L., Moody, S. A. & Knox, B. E. Characterization of the Xenopus rhodopsin gene. J Biol Chem 271, 3179–3186 (1996).
40. Karpinka, J. B. et al. Xenbase, the Xenopus model organism database; new virtualized system, data types and genomes. Nucleic Acids Res. 43, D756–D763 (2015).
41. Nakayama, T. et al. Simple and efficient CRISPR/Cas9-mediated targeted mutagenesis in Xenopus tropicalis. Genesis 51, 835–43 (2013).
42. Nieuwkoop, P. D. & Faber, J. Normal table of Xenopus laevis (Daudin): a systematical and chronological survey of the development from the fertilized egg till the end of metamorphosis. (Garland Pub., 1994).
43. Vouillot, L., Thélie, A. & Pollet, N. Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 (Bethesda). 5, 407–15 (2015).
44. Knight, S. C. et al. Dynamics of CRISPR-Cas9 genome interrogation in living cells. Science (80-.). 350 (2015).
45. Fa, G. H. & Lieber, M. R. Mechanistic constraints on diversity in human V(D) recombination. Mol. Cell. Biol. 16, 258–69 (1996).
46. Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181–211 (2010).
47. Tam, R. M. & Moritz, O. L. Characterization of rhodopsin P23H-induced retinal degeneration in a Xenopus laevis model of retinitis pigmentosa. Invest Ophtalmol Vis Sci 47, 3234–3241 (2006).
48. Wang, H. et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. Cell 153, 916–918 (2013).
49. Yang, H. et al. One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering. Cell 154, 1370–1379 (2013).
50. Yoon, W. S., Tam, B. M., Papermaster, D. S. & Nakayama, T. A functional rhodopsin:green fluorescent protein fusion protein localizes correctly in transgenic Xenopus laevis retinal rods and is expressed in a time-dependent pattern. J Biol Chem 276, 28242–28251 (2001).
51. Jin, S., Cornwall, M. C. & Oprian, D. D. Opsin activation as a cause of congenital night blindness. Nat. Neurosci. 6, 731–5 (2003).
52. Jin, S., McKee, T. D. & Oprian, D. D. An improved rhodopsin/EGFP fusion protein for use in the generation of transgenic Xenopus laevis. FEBS Lett. 542, 142–6 (2003).
53. Chen, F. et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat. Methods 8, 753–755 (2011).
54. Tam, B. M., Xie, G., Oprian, D. D. & Moritz, O. L. Mislocalized rhodopsin does not require activation to cause retinal degeneration and neurite outgrowth in Xenopus laevis. J Neurosci 26, 203–209 (2006).
55. Lieberman, P. A. In situ microspectrophotometric studies on the pigments of single retinal rods. Biophys. J. 2, 161–78 (1962).
56. Mortiz, O. L. & Tam, B. M. Recent insights into the mechanisms underlying light-dependent retinal degeneration from X. Laevis models of retinitis pigmentosa. Adv Exp Med Biol 664, 509–515 (2010).
57. Lin, J. H. et al. IRE1 signaling affects cell fate during the unfolded protein response. Science (80-.). 318, 944–949 (2007).
58. Lobanova, E. S., Finkelstein, S., Skiba, N. P. & Arshavsky, V. Y. Proteasome overload is a common stress factor in multiple forms of inherited retinal degeneration. Proc. Natl Acad. Sci. USA 110, 9986–99 (2013).
59. Schroeder, M. & Kaufman, R. J. The mammalian unfolded protein response. Annu Rev Biochem 74, 739–789 (2005).
60. Rosenfeld, P. J. et al. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat. Genet. 1, 209–13 (1992).
61. Makino, C. L. et al. Rhodopsin expression level affects rod outer segment morphology and photoreceptor kinetics. PLoS One 7, e37832 (2012).
62. Bi, X.-H. et al. Overexpression of rhodopsin alters the structure and phototransduction of rod photoreceptors. Biophys. J. 96, 939–50 (2009).
63. Price, B. A. et al. Rhodopsin gene expression determines rod outer segment size and rod cell resistance to a dominantly-negative neurodegeneration mutant. PLoS One 7, e49889 (2012).
64. Gross, A. K. et al. Defective development of photoreceptor membranes in a mouse model of recessive retinal degeneration. Vision Res. 46, 4510–8 (2006).
65. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538–542 (2015).
66. Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543–548 (2015).

Acknowledgements
This research was funded by the National Sciences and Engineering Research Council of Canada (NSERC) and the Foundation Fighting Blindness (Canada). Thanks to R.S. Molday and W.C. Smith for kindly providing the antibodies used in these studies.

Author Contributions
J.F. and O.M. designed experiments, J.F., C.C., P.S., B.T., and S.A. carried out experiments. J.F. and O.M. wrote the manuscript. J.F., C.C., P.S., B.T., and O.M. edited the manuscript. O.M. obtained funding.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-07153-4

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017